CT-guided Percutaneous Radionuclide Therapy With 32P Microparticles in Patients With Non-progressive Locally Advanced Pancreatic Cancer

Inclusion Criteria: * Age ≥18 years * Locally advanced pancreatic cancer, defined by the DPCG consensus criteria as: arterial involvement \>90 degrees or venous involvement \>270 degrees. * At least RECIST stable disease after a minimum two months of chemotherapy according to current clinical practice\* * Capable of providing written and oral informed consent * Candidate for RNT, judged by a multidisciplinary tumor board * WHO 0-2 Exclusion Criteria: * Eligibility for resection * Participation in other trials focussing on different ablative treatment modalities such as radiofrequency ablation or irreversible electroporation for LAPC * Known hypersensitivity to silicon or phosphor * Bleeding disorders which cannot be corrected with medication * Inability/unwillingness to interrupt anticoagulation therapy * Pregnancy * Metastatic pancreatic cancer * Epilepsy episode(s) in the past six months * Longest tumor diameter \>70 mm or total target tumor volume \>110 ml * Presence of multiple collateral vessels surrounding or adjacent to the target tumor on radiologic imagining, prohibiting safe injection of the OncosilTM device * Presence (or significant risk) of varices near the target tumor on radiologic imaging * Recent clinically significant pancreatitis * Previous administration of radiotherapy to the pancreas